The association between antidepressant use and hypoglycaemia in diabetic patients: A nested case-control study

Pharmacoepidemiology and Drug Safety

Volumn 17, Issue 4, 2008, Pages 336-344

  Derijks, Hieronymus J ^a,b   Heerdink, Eibert R ^a   De Koning, Fred H ^a,c   Janknegt, Robert ^b   Klungel, Olaf H ^a   Egherts, Antoine C ^a,d  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Sittard Geleen Heerlen   (Netherlands)

^c Association Kring Apothekin The Netherlands   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Adverse drug reactions; Antidepressive agents; Diabetes mellitus; Drug safety; Hypoglycaemia

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DOXEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; INSULIN; MAPROTILINE; MIANSERIN; MIRTAZAPINE; NORTRIPTYLINE; ORAL ANTIDIABETIC AGENT; PAROXETINE; SERTRALINE; TRAZODONE; VENLAFAXINE; ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CASE CONTROL STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; FEMALE; GLUCOSE HOMEOSTASIS; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PRIORITY JOURNAL; RECEPTOR BINDING; SELF MONITORING; ADOLESCENT; CHEMICALLY INDUCED DISORDER; DEPRESSION; DRUG EFFECT; DRUG INTERACTION; EPIDEMIOLOGY; GLUCOSE BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; MEDICAL RECORD; METABOLISM; METHODOLOGY; MIDDLE AGED; PHARMACOEPIDEMIOLOGY; RISK FACTOR;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); DEPRESSIVE DISORDER; DIABETES MELLITUS, TYPE 1; DRUG INTERACTIONS; FEMALE; HOSPITALIZATION; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MEDICAL RECORD LINKAGE; MIDDLE AGED; PHARMACOEPIDEMIOLOGY; RISK FACTORS;

EID: 42149106894     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1562     Document Type: Article

References (53)

1. Goodnick PJ, Henry JH, Buld VM. Treatment of depression in patients with diabetes mellitus. J Clin Psychiatry 1995; 56(4): 128-136.
2. Moosa MY, Panz VR, Jeenah FY, Joffe BI. African women with depression: the effect of imipramine and fluoxetine on body mass index and leptin secretion. J Clin Psychopharmacol 2003; 23(6): 549-552.
3. Derijks HJ, De Koning FH, Meyboom RH, Heerdink ER, Spooren PF, Egberts AC. Impaired glucose homeostasis after imipramine intake in a diabetic patient. J Clin Psychopharmacol 2005; 25(6): 621-623.
4. DCCT. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329(14): 977-986.
5. UKPDS. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131): 854-865.
6. UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131): 837-853.
7. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000; 321(7258): 405-412.
8. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia 2002; 45(7): 937-948.
9. Laing SP, Swerdlow AJ, Slater SD, et al. The British Diabetic Association Cohort Study, II: cause-specific mortality in patients with insulin-treated diabetes mellitus. Diabet Med 1999; 16(6): 466-471.
10. Petersen T, Iosifescu DV, Papakostas GI, Shear DL, Fava M. Clinical characteristics of depressed patients with comorbid diabetes mellitus. Int Clin Psychopharmacol 2006; 21(1): 43-47.
11. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001; 24(6): 1069-1078.
12. Peyrot M, Rubin RR. Levels and risks of depression and anxiety symptomatology among diabetic adults. Diabetes Care 1997; 20(4): 585-590.
13. Gomez R, Huber J, Lhullier F, Barros HM. Plasma insulin levels are increased by sertraline in rats under oral glucose overload. Braz J Med Biol Res 2001; 34(12): 1569-1572.
14. Gomez R, Huber J, Tombini G, Barros HM. Acute effect of different antidepressants on glycemia. in diabetic and non-diabetic rats. Braz J Med Biol Res 2001; 34(1): 57-64.
15. Erenmemisoglu A. Ozdogan UK, Saraymen R, Tutus A. Effect of some antidepressants on glycaemia and insulin levels of normoglycaemic and alloxan-induced hyperglycaemic mice. J Pharm Pharmacol 1999; 51(6): 741-743.
16. El-Dakhakhny M, Abdel el-Latif HA, Ammon HP. Different effects of the antidepressant drugs imipramine, maprotiline, and bupropion on insulin secretion from mouse panceatic islets. Arzneimitteiforshung 1996; 46(7): 667-669.
17. Sawka AM, Burgart V, Zimmerman D. Loss of awareness of hypoglycemia temporally associated with selective serotonin reuptake inhibitors. Diabetes Care 2001; 24(10): 1945-1846.
18. Sawka AM, Burgart V, Zimmerman D. Loss of hypoglycemia awareness in an adolescent with type 1 diabetes mellitus during treatment with fluoxetine hydrochloride. J Pediatr 2000; 136(3): 394-396.
19. Deeg MA, Lipkin EW. Hypoglycemia associated with the use of fluoxetine. West J Med 1996; 164(3): 262-263.
20. Pollak PT, Mukherjee SD, Fraser AD. Sertraline-induced hypoglycemia. Ann Pharmacother 2001; 35(11): 1371-1374.
21. Takhar J, Williamson P. Hypoglycemia associated with high doses of sertraline and sulphonylurea, compound in a noninsulin-dependent diabetes mellitus patient. Can J Clin Pharmacol 1999; 6(1): 12-14.
22. Sherman KE, Bornemann M. Amitriptyline and asymptomatic hypoglycemia. Ann Intern Med 1988; 109(8): 683-684.
23. True BL, Perry PJ, Burns EA. Profound hypoglycemia with the addition of a tricyclic antidepressant to maintenance sulfonylurea. therapy. Am J Psychiatry 1987; 144(9): 1220-1221.
24. Isotani H, Kameoka K. Hypoglycemia associated with maprotiline in a patient with type 1 diabetes. Diabetes Care 1999; 22(5): 862-863.
25. Warnock JK. Nefazodone-induced hypoglycemia in a diabetic patient with major depression. Am J Psychiatry 1997; 154: 288-289.
26. Maheux P, Ducros F, Bourque J. Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss. Int J Obesity 1997; 21(2): 97-102.
27. Connolly VM, Gallagher A, Kesson CM. A study of fluoxetine in obese elderly patients with type 2 diabetes. Diabet Med 1995; 12: 416-418.
28. Potter van Loon. BJ, Radder JK, Frolich M, Krans HM, Zwinderman AH, Meinders AE. Fluoxetine increases insulin action in obese nondiabetic and in obese non-insulin-dependent diabetic individuals. In J Obes Relat Metab Disord 1992; 16(2): 79-85.
29. Gray DS, Fujioka K, Devine W. Fluoxetine in the treatment of the obese diabetic. Int J Obesity 1992; 16(2): 79-85.
30. Ghaeli P, Shahsavand E, Mesbahi M, Kamkar MZ, Sadeghi M, Dashti-Khavidaki S. Comparing the effects of 8-week treatment with fluoxetine and imipramine on fasting blood glucose of patients with major depressive disorder J Clin Psychopharmacol 2004; 24(4): 386-388.
31. Herings RM, Bakker A, Stiricker BH, Nap G. Pharmacomorbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. J Epidemiol Community Health 1992; 46(2): 136-440.
32. Mantel-Teeuwisse AK, Klungel OH, Verschuren WM, Porsius A, de Boer A. Comparison of different methods to estimate prevalence of drug use by using pharmacy records. J Clin Epidemiol 2001; 54(11): 1181-1186.
33. Pandit MK, Burke J, Gustafson AB, Minocha A, Peiris AN. Drug-induced disorders of glucose tolerance. Ann Intern Med 1993; 118(7): 529-539.
34. Dwyer DS, Bradley RJ, Kablinger AS, Freeman AM, 3rd. Glucose metabolism in relation to schizophrenia and antipsychotic drug treatment. Ann Clin Psychiatry 2001; 13(2): 103-113.
35. Herings RM, de Boer A, Stricker BH, Leufklens HG, Porsius A. Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme. Lancet 1995; 345(8959): 1195-1198.
36. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992; 45(2): 197-203.
37. Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public Health 1989; 79(3): 340-349.
38. Larsen PR, Kronenberg MN, Metmed S, Polonsky KS. Williams Textbook of Endocrinology. Saunders: Philadelphia, 2003.
39. Araya V, Contreras P, Aguirre C, Depix MS, Zura ML. The effect of fluoxetine on insulin resistance in non diabetic obese patients. Rev Med Chil 1995; 123(8): 943-947.
40. Scheen AJ, Paolisso G, Salvatore T, Lefebvre PJ. Improvement of insulin-induced glucose disposal in obese patients with NIDDM after 1-wk treatment with d-fenfluramine. Diabetes Care 1991; 14(4): 325-332.
41. Pestell RG, Crock PA, Ward GM. Fenfluramine increases action in patients with NIDDM. Diabetes Care 1989; 12: 252-258.
42. Furman BL, Wilson GA. Further studies on the effects of 5-hydroxytryptophan on plasma glucose and insulin in the mouse. Diabetologia 1980(19): 386-390.
43. Yamada J, Sugimoto Y, Kimura I, Takeuchi N, Horisaka K. Serotonin-induced hypoglycaemia. and increased serum insulin levels in mice. Life Sci 1989; 45: 1931-1936.
44. Yamada J, Sugimoto Y, Kimura I, Takeuchi N, Horisaka K. The activation of serotonin receptors by tryptamine induces hyperinsulnemia in mice. Eur J Pharmacol 1990; 181: 319-322.
45. Donnelly LA, Morris AD, Frier BM, et al. Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study. Diabet Med 2005; 22(6): 749-755.
46. Van der Does FE, De Neeling JN, Snoek FJ, et al. Symptoms and well-being in relation to glycemic control in type II diabetes. Diabetes Care 1996; 19(3): 204,210.
47. Van Tilburg MA, McCaskill CC, Lane JD, et al. Depressed mood is a factor in glycemic control in type 1 diabetes. Psychosom Med 2001; 63(4): 551-555.
48. Lustman PJ, Freedland KE, Griffith LS, Clouse RE. Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. Diabetes Care 2000; 23(5): 618-623.
49. Paile-Hyvarinen M, Wahlbeck K, Eriksson JG. Quality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine: a single-blind randomised placebo controlled trial. BMC Fam Pract 2003; 4: 7.
50. Goodnick PJ, Kumar A, Henry JH, Buki VM, Goldberg RB. Sertraline in coexisting major depression and diabetes mellitus. Psychopharmacol Bull 1997; 33(2): 261-264.
51. Lustman PJ, Clouse RE, Nix BD, et al. Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 2006; 63(5): 521-529.
52. Ito K, Ohtani H, Sawada Y. Assessment of the alpha-adorenoceptor antagonists in benign prostatic hyperplasia based on the receptor occupancy theory. Br J Clin Pharmacol 2007; 63(4): 394-403.
53. Yamada Y, Takayanagi R, Tsuchiya K, et al. Assessment of systemic adverse reactions induced by ophthalmic beta-adrenergic receptor antagonists. J Ocul Pharmacol Ther 2001; 17(3): 235-248.